Trends in Hidradenitis Suppurativa Disease Severity and Quality of Life Outcome Measures: Scoping Review

Overview

Journal JMIR Dermatol

Specialty Dermatology

Date 2023 Aug 26

PMID 37632807

Authors

Jalal Maghfour

Torunn Elise Sivesind

Robert Paul Dellavalle

Cory Dunnick

Affiliations

Soon will be listed here.

Abstract

Background: Although there has been an increase in the number of randomized controlled trials evaluating treatment efficacy for hidradenitis suppurativa (HS), instrument measurements of disease severity and quality of life (QoL) are varied, making the compilation of data and comparisons between studies a challenge for clinicians.

Objective: We aimed to perform a systematic literature search to examine the recent trends in the use of disease severity and QoL outcome instruments in randomized controlled trials that have been conducted on patients with HS.

Methods: A scoping review was conducted in February 2021. The PubMed, Embase, Web of Science, and Cochrane databases were used to identify all articles published from January 1964 to February 2021. In total, 41 articles were included in this systematic review.

Results: The HS Clinical Response (HiSCR) score (18/41, 44%) was the most commonly used instrument for disease severity, followed by the Sartorius and Modified Sartorius scales (combined: 16/41, 39%). The Dermatology Life Quality Index (18/41, 44%) and visual analogue pain scales (12/41, 29%) were the most commonly used QoL outcome instruments in HS research.

Conclusions: Randomized controlled trials conducted from 2013 onward commonly used the validated HiSCR score, while older studies were more heterogeneous and less likely to use a validated scale. A few (6/18, 33%) QoL measures were validated instruments but were not specific to HS; therefore, they may not be representative of all factors that impact patients with HS.

Trial Registration: National Institute of Health Research PROSPERO CRD42020209582; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020209582.

Citing Articles

A Clinicodemographic Study of Indian Patients with Hidradenitis Suppurativa and its Association with Metabolic Syndrome.

De D, Baskaran N, Thakur V, Hanumanthu V, Bakshi S, Bhandari S Indian Dermatol Online J. 2024; 15(6):963-970.

PMID: 39640442 PMC: 11616909. DOI: 10.4103/idoj.idoj_330_24.

Trends in disease severity and quality of life outcome measures in pemphigus clinical trials: A scoping review.

Pathak G, Patel K, Wachuku C, Truong T, Agarwal P, Rao B Skin Health Dis. 2024; 4(5):e429.

PMID: 39355721 PMC: 11442060. DOI: 10.1002/ski2.429.

References

Kimball A, Sundaram M, Banderas B, Foley C, Shields A . Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa. J Dermatolog Treat. 2017; 29(2):152-164. DOI: 10.1080/09546634.2017.1341614. View

Vellaichamy G, Braunberger T, Jones J, Peacock A, Nahhas A, Hamzavi I . Patient-reported outcomes in hidradenitis suppurativa. G Ital Dermatol Venereol. 2018; 154(2):137-147. DOI: 10.23736/S0392-0488.18.06021-2. View

Zouboulis C, Tzellos T, Kyrgidis A, Jemec G, Bechara F, Giamarellos-Bourboulis E . Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017; 177(5):1401-1409. DOI: 10.1111/bjd.15748. View

Tchero H, Herlin C, Bekara F, Fluieraru S, Teot L . Hidradenitis Suppurativa: A Systematic Review and Meta-analysis of Therapeutic Interventions. Indian J Dermatol Venereol Leprol. 2019; 85(3):248-257. DOI: 10.4103/ijdvl.IJDVL_69_18. View

Yildiz H, Senol L, Ercan E, Bilgili M, Abuaf O . A prospective randomized controlled trial assessing the efficacy of adjunctive hyperbaric oxygen therapy in the treatment of hidradenitis suppurativa. Int J Dermatol. 2015; 55(2):232-7. DOI: 10.1111/ijd.12936. View

Wilden S, Friis M, Tuettenberg A, Staubach-Renz P, Wegner J, Grabbe S . Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF). J Dermatolog Treat. 2019; 32(5):530-537. DOI: 10.1080/09546634.2019.1677842. View

Dufour D, Emtestam L, Jemec G . Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014; 90(1062):216-21. PMC: 3963556. DOI: 10.1136/postgradmedj-2013-131994. View

Zouboulis C, Okun M, Prens E, Gniadecki R, Foley P, Lynde C . Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2018; 80(1):60-69.e2. DOI: 10.1016/j.jaad.2018.05.040. View

Schultheis M, Staubach P, Nikolakis G, Grabbe S, Ruckes C, von Stebut E . LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial. Dermatology. 2021; 238(3):476-486. DOI: 10.1159/000518540. View

10.

Fadel M, Tawfik A . New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study. Clin Exp Dermatol. 2014; 40(2):116-22. DOI: 10.1111/ced.12459. View

11.

Highton L, Chan W, Khwaja N, Laitung J . Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg. 2011; 128(2):459-466. DOI: 10.1097/PRS.0b013e31821e6fb5. View

12.

Adams D, Yankura J, Fogelberg A, Anderson B . Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010; 146(5):501-4. DOI: 10.1001/archdermatol.2010.72. View

13.

Gottlieb A, Menter A, Armstrong A, Ocampo C, Gu Y, Teixeira H . Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study. J Drugs Dermatol. 2016; 15(10):1192-1196. View

14.

Kimball A, Okun M, Williams D, Gottlieb A, Papp K, Zouboulis C . Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016; 375(5):422-34. DOI: 10.1056/NEJMoa1504370. View

15.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

16.

Thorlacius L, Esmann S, Miller I, Vinding G, Jemec G . Development of HiSQOL: A Hidradenitis Suppurativa-Specific Quality of Life Instrument. Skin Appendage Disord. 2019; 5(4):221-229. PMC: 6615484. DOI: 10.1159/000496234. View

17.

Willems D, Hiligsmann M, van der Zee H, Sayed C, Evers S . Identifying Unmet Care Needs and Important Treatment Attributes in the Management of Hidradenitis Suppurativa: A Qualitative Interview Study. Patient. 2021; 15(2):207-218. PMC: 8349666. DOI: 10.1007/s40271-021-00539-7. View

18.

Sartorius K, Emtestam L, Jemec G, Lapins J . Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009; 161(4):831-9. DOI: 10.1111/j.1365-2133.2009.09198.x. View

19.

Giamarellos-Bourboulis E, Sobell J, Ryan C, Wolkenstein P, Geng Z, Mulder G . Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies. Wounds. 2017; 29(11):E98-E102. View

20.

Vossen A, van Doorn M, van der Zee H, Prens E . Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. J Am Acad Dermatol. 2018; 80(1):80-88. DOI: 10.1016/j.jaad.2018.06.046. View